post myocardial infarction

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathNon fatal MI

anti inflammatory drugs

not classified
CANTOS, 2017      NCTcanakinumab placeboLow risk of bias remark

antiarrythmic drugs

not classified
BASIS, 1990   class I drugscontrol -
CAST I, 1991    NCTplaceboLow risk of bias -
Julian, 1982     d,l sotalolplaceboLow risk of bias -
amiodarone
BASIS, 1990   early amiodaronecontrolsuggesting-59%
Navarro-Lopez, 1993   early amiodaronecontrolnegative-52%
CAMIAT , 1991   early amiodaroneplaceboLow risk of bias negative-18%
Ceremuzynski, 1992   early amiodaroneplaceboLow risk of bias negative-37%
Hockings, 1987     early amiodaroneplaceboLow risk of bias negative94%
Azimilide
ALIVE, 2004       azimilideplaceboLow risk of bias -
dofetilide
DIAMOND MI, 1997   dofetilideplaceboLow risk of bias -
moricizine
CAST II (early treatment), 1992   moricizineplaceboLow risk of bias -
CAST II (late treatment), 1992   moricizineplaceboLow risk of bias -

anticoagulant

not classified
Sixty Plus reinfarction Study, 1980   any anticoagulantplaceboLow risk of bias -
German-Austrian Study Group (oac vs pbo), 1980   phenprocoumonplaceboLow risk of bias negative14%
EPSIM, 1982   any anticoagulantaspirinnegative-10%
German-Austrian Study Group (oac vs asp), 1980   phenprocoumonaspirinLow risk of bias negative 43%
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative -42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting -10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting-72%
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative -67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting -5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting -2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 3%

antioxydants

not classified
ARISE, 2007      NCTsuccinobucolplaceboLow risk of bias -

antiplatelets drug

aspirin
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%-11%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%-53%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%-22%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%-29%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%-30%
JAMIS, 1999     aspirinplacebosuggesting18%-73%
clopidogrel
CAPRIE, 1996     clopidogrelaspirinLow risk of bias -
dipyridamol
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative
ticagrelor
PEGASUS 60mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -11%
PEGASUS 90mg, 2015        NCTticagrelorplacebo (on top aspirin)secondary preventionLow risk of bias suggesting 0%
vorapaxar
TRA-2P TIMI 50, 2012        NCTvorapaxarplacebo (on top aspirin)secondary preventionLow risk of bias suggesting -4%

antithrombotics

dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative

calcium channel blockers

diltiazem
MDPIT, 1988   diltiazemplaceboLow risk of bias negative0%
nifedipine
MI study group, 1979   nifedipine -
SPRINT I, 1988   nifedipineplaceboLow risk of bias negative1%
SPRINT II, 1993   nifedipineplaceboLow risk of bias negative16%
verapamil
DAVIT I, 1984   verapamilplaceboLow risk of bias -
DAVIT II, 1990   verapamilplaceboLow risk of bias negative-18%
CRIS, 1996     verapamilplaceboLow risk of bias negative6%
Danish study, 1984     verapamilplaceboLow risk of bias negative

cholesterol lowering intervention

atorvastatin
TNT, 2005            NCTatorvastatin high doseatorvastatinsecondary preventionLow risk of bias conclusive 1%-21%
Vascular basis, 2005     atorvastatin high doselovastatinsecondary preventionExploratory negative+Infini%
REVERSAL, 2004     atorvastatin high dosepravastatinsecondary preventionExploratory negative
SAGE, 2007     atorvastatin high dosepravastatinsecondary preventionExploratory suggesting-67%-6%
IDEAL, 2005        NCTatorvastatin high dosesimvastatinsecondary preventionRisk of bias suggesting -2%-17%
bezafibrate
BECAIT, 1996     bezafibrateplacebosecondary preventionExploratory suggesting+Infini%
BIP, 2000       bezafibrateplacebosecondary preventionLow risk of bias negative6%-13%
diet
Tuttle, 2008     low fat dietmediterranean-style dietRisk of bias -
ezetimibe
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-1%
gemfibrozil
VA-HIT, 1999      NCTgemfibrozilplaceboLow risk of bias suggesting-10%-20%
niacin
Carlson (Stockholm), 1977   clofibtate+niacinplacebosecondary preventionRisk of bias suggesting-26%-31%
pravastatin
PACT, 2004     pravastatinplacebosecondary preventionLow risk of bias negative-36%7%
LIPID, 1998         pravastatinplacebosecondary preventionLow risk of bias conclusive-22%
CARE, 1996       pravastatinplacebosecondary preventionLow risk of bias conclusive-8%-22%
simvastatin
4S, 1994   simvastatinplacebosecondary preventionLow risk of bias conclusive-29%-33%

omega-3 fatty acids

not classified
OMEGA, 2009      NCTomega-3 Fatty acidscontrolRisk of bias negative 23%

secondary prevention

aspirin
CDPA, 1976   aspirinplaceboLow risk of bias negative-30%-11%
Cardiff I, 1974   aspirinplaceboLow risk of bias negative-26%
Cardiff II, 1979   aspirinplaceboLow risk of bias negative-17%
Vogel, 1979   aspirinplaceboLow risk of bias suggesting-32%-53%
AMIS, 1980    NCTaspirinplaceboLow risk of bias suggesting11%-22%
GAMIS, 1980   aspirinplaceboLow risk of bias negative-18%-29%
PARIS, 1980   aspirinplaceboLow risk of bias negative-18%-30%
JAMIS, 1999     aspirinplacebosuggesting18%-73%
clopidogrel
CAPRIE, 1996     clopidogrelaspirinLow risk of bias -
dipyridamol
PARIS, 1980   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS-II, 1986   dipyridamol + aspirinplaceboLow risk of bias negative
PARIS, 1980   dipyridamol + aspirinaspirinLow risk of bias negative